REG - IQ-AI Limited - IB Expands Distribution with Blackford

IQ-AIAnnouncement

03/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250203:nRSC5554Va&default-theme=true

RNS Number : 5554V  IQ-AI Limited  03 February 2025

February 3, 2025

 

Imaging Biometrics Expands Distribution with Blackford

 

Imaging Biometrics, LLC (IB), Elm Grove, WI, a wholly owned subsidiary of
IQ-AI Ltd (LSE: IQAI), has amended their existing distribution agreement with
AI platform provider Blackford Analysis Ltd (Blackford). The amendment adds IB
Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing
Blackford to also sell these products to their growing global client base.

 

Acquired by Bayer in early 2023, Blackford is a pioneer in the healthcare AI
platform and solutions sphere, offering healthcare providers a pathway to a
comprehensive list of 140+ curated AI applications from various trusted
vendors via a trusted centralized platform point of entry. This approach
simplifies accessibility and streamlines the integration and deployment of
advanced AI technology, optimizing workflows and ultimately benefiting patient
care.

 

IB Nimble remains an independent mobile application but will interface with
Blackford's Enterprise AI platform. Compatible with both iOS and Android, it
facilitates secure, real-time collaboration among multi-disciplinary medical
experts-a technology of high interest to Blackford.

 

"We see strong growth potential in using mobile technology across the
healthcare enterprise. IB Nimble has the ability to connect key clinicians
through secure, real-time collaboration. By enhancing communication and
streamlining treatment decisions, it ultimately supports more effective and
efficient patient care," says Ben Panter, Founder and CEO of Blackford.

 

IB ASL is a new product that incorporates arterial spin labeling ("ASL").
Available via a Blackford platform integration, ASL is a perfusion approach
that complements IB Neuro. Instead of using an injected contrast agent, ASL
uses the body's own blood. Its clinical application has grown particularly for
measuring blood flow (as opposed to blood volume) in the care of patients who
suffered a stroke.

 

The FTB mapping technologies, which offer exclusive benefits to
neuro-oncologists and surgeons for the treatment of vascular brain tumors like
glioblastoma and brain metastases, are available through Blackford's AI
platform.

 

"We appreciate Blackford's continued interest in our quantitative applications
like FTB mapping, and are excited for the early and strong interest of IB
Nimble," said Michael Schmainda, CEO of IB.

 

-ENDS-

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

  IQ-AI Ltd

 Trevor Brown/Al Musella/Brett Skelly/Michael Schmainda

 Tel: 020 7469 0930
 Peterhouse Capital Limited (Financial Adviser and Broker)

 Tel: 020 7220 9797

 

About Imaging Biometrics® LLC
IB is a wholly owned subsidiary of IQ-AI Limited, (LSE: IQAI), delivering
quantitative imaging platforms and therapeutics which transform how clinicians
diagnose and treat patients, making them more efficient and effective. For
more information about Imaging Biometrics, visit the company's website at
www.imagingbiometrics.com (http://www.imagingbiometrics.com/) . Follow IB on
X @IQAI_IB.

 

About Blackford Analysis, Ltd

Blackford are pioneers in the radiology AI space, with over a decade of
experience working in partnership with leading hospitals and ground-breaking
technology providers. We operate as an Enterprise AI partner, providing access
to a tried-and-tested core platform, tailored services, and a portfolio of
140+ applications to help healthcare providers unlock the value of AI and
improve patient outcomes.

Our collaboration and arms-length acquisition by Bayer ensures that our
customers and partners have the support and long-term security needed to
underpin successful AI strategies.

To learn more about Blackford's tailored approach to AI solutions visit
www.blackfordanalysis.com (http://www.blackfordanalysis.com/) , and follow us
on X (https://twitter.com/blackford) and LinkedIn
(https://www.linkedin.com/company/blackford-analysis-ltd/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUAAURVAUURAR